Background: Visceral hypersensitivity is claimed to be involved in the pathogenesis of nonulcer dyspepsia (NUD). In a double-blind crossover study, we evaluated the effects of tropisetron, a 5-HT3 receptor antagonist, on gastric accommodation, reflex relaxation, and sensitivity in NUD patients.
Methods: Eight patients and 10 healthy controls received placebo or 5 mg tropisetron on separate days. On each day, gastric accommodation and relaxation were investigated using a gastric barostat. The perception during gastric distension and relaxation was scored by a verbal perception score.
Results: Under both medications, gastric accommodation and postprandial gastric reflex relaxation were not impaired in the NUD patients. The visceral perception was increased in the NUD patients and not substantially influenced by tropisetron.
Conclusions: Tropisetron does not influence gastric accommodation, reflex relaxation, or gastric sensitivity in NUD patients and healthy controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000007640 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review.
Cancer Treat Rev
January 2025
Upper Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Neuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving response no consensus exists on maintenance therapies and the results are inconsistent. This review examines the role of maintenance therapy following response to first-line chemotherapy in gastroenteropancreatic neuroendocrine carcinomas.
View Article and Find Full Text PDFNeoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical Trial.
Ann Surg
December 2024
Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
Objective: This clinical trial investigated the safety and efficacy of single-cycle pembrolizumab in patients with localized deficient mismatch repair (dMMR) colon cancer.
Background: Neoadjuvant immunotherapy has induced remarkable rates of pathological complete response in patients with dMMR colon cancer. However, the optimal length and type of treatment are yet to be determined.
Validated approaches at mayo clinic for measuring gastric and colonic transit of solids and gastric accommodation.
Expert Rev Gastroenterol Hepatol
November 2024
Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology; Division of Nuclear Medicine, Department of Radiology Mayo Clinic, Rochester, MN, USA.
Introduction: Advancements in scintigraphic gastrointestinal motility testing that were developed, validated, and replicated in clinical practice at Mayo Clinic have significantly enhanced our understanding and management of gastrointestinal motility disorders. Importantly, normative values in at least 100 healthy controls and estimated inter- and intra-individual coefficient of variation for all parameters have been published for these tests.
Areas Covered: This article reviews methodology, accuracy, reproducibility, and diagnostic cutoffs of scintigraphic techniques for measuring gastric emptying, gastric accommodation, and colonic transit, comparing methods from Mayo Clinic with those used elsewhere when appropriate.
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments.
J Physiol
November 2024
Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
The aims of this review are to appraise the role of the stomach in satiation, the effects of incretin and other hormone agonists on weight loss and the role of altered gastric functions in their effects on obesity or glycaemic control. In addition to the gut in its role in enzymatic digestion and hormonal responses to nutrient ingestion, gastric motor functions include accommodation, trituration and emptying [gastric emptying (GE)] of food and elicitation of postprandial satiation and satiety. The postprandially released hormones most extensively studied and utilized therapeutically are glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
View Article and Find Full Text PDFSalcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.
J Control Release
January 2025
Novo Nordisk A/S, Global Research Technologies, 2760 Måløv, Denmark.
Oral delivery of peptides requires formulations with high concentrations of permeation enhancer (PE) to promote absorption, and often necessitates fasting time between dosing and food ingestion. Improved formulations promoting a more rapid absorption would increase convenience of use but requires a faster onset of action. We have developed a salcaprozate-based ionic liquid (IL) formulation, namely choline salcaprozate (CHONAC), for oral delivery of a glucagon-like peptide-1 (GLP-1) analogue via gastric absorption.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!